Literature DB >> 8611461

Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation.

Z Xia1, T Wong, Q Liu, A Kasirer-Friede, E Brown, M M Frojmovic.   

Abstract

Dynamic and quantitative studies of the binding of fibrinogen (Fg) to its receptor, GPIIb-IIIa, on activated platelets, leading to platelet aggregation, are best studied with fluorescently-labelled Fg by flow cytometry. Due to conflicting reports on the functionality of FITC-labelled Fg, we have developed a reproducible and 'mild' labelling of fibrinogen with FITC-celite at pH 7.4-8.5 for direct and dynamic studies of specific Fg binding to activated platelets evaluated for native platelet-rich plasma, for washed platelets, and for activated, fixed platelets. We have demonstrated the equivalence of FITC-labelled and unlabelled Fg for binding to activated GPIIb-IIIa receptors, and in the rate and extent of mediating platelet aggregation. We found that FITC-Fg labelled at pH > or = 9 had reduced to absent specific binding to activated platelets, whether using soluble FITC or FITC-celite. The FITC-labelled Fg must be diluted 3-fold with unlabelled Fg when evaluating maximal Fg binding to activated platelets in order to prevent autoquenching of the FITC-Fg which leads to underestimation of Fg levels. The dissociation constant (KD) of Fg on stable preparations of activated, fixed platelets, determined with FITC-Fg binding to platelets by flow cytometry, was in the range reported for 125I-labelled Fg, 70-255 nm with Bmax = 10000-25000 Fg per platelet (n = 20). The FITC-Fg was used to monitor Fg binding to activated platelets directly by plasma, as well as to evaluate platelet subpopulations which maximally bind Fg according to the concentration of ADP used as activator. It is expected that this 'mildly' labelled FITC-Fg will stimulate further studies of platelet activation directly in native anticoagulated blood/plasma, for both basic and clinical research.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8611461     DOI: 10.1046/j.1365-2141.1996.445980.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

1.  Time and force dependence of the rupture of glycoprotein IIb-IIIa-fibrinogen bonds between latex spheres.

Authors:  H L Goldsmith; F A McIntosh; J Shahin; M M Frojmovic
Journal:  Biophys J       Date:  2000-03       Impact factor: 4.033

2.  Critical cysteine residues for regulation of integrin alphaIIbbeta3 are clustered in the epidermal growth factor domains of the beta3 subunit.

Authors:  Tetsuji Kamata; Hironobu Ambo; Wilma Puzon-McLaughlin; Kenneth Khiem Tieu; Makoto Handa; Yasuo Ikeda; Yoshikazu Takada
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

3.  Efficiency of platelet adhesion to fibrinogen depends on both cell activation and flow.

Authors:  A Bonnefoy; Q Liu; C Legrand; M M Frojmovic
Journal:  Biophys J       Date:  2000-06       Impact factor: 4.033

4.  Dynamic regulation of fibrinogen: integrin αIIbβ3 binding.

Authors:  Roy R Hantgan; Mary C Stahle; Susan T Lord
Journal:  Biochemistry       Date:  2010-11-02       Impact factor: 3.162

5.  Magnetic resonance molecular imaging of thrombosis in an arachidonic acid mouse model using an activated platelet targeted probe.

Authors:  Ahmed Klink; Eric Lancelot; Sébastien Ballet; Esad Vucic; Jean-Etienne Fabre; Walter Gonzalez; Christelle Medina; Claire Corot; Willem J M Mulder; Ziad Mallat; Zahi A Fayad
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-02-05       Impact factor: 8.311

6.  Platelet factor 4 mediates inflammation in experimental cerebral malaria.

Authors:  Kalyan Srivastava; Ian A Cockburn; AnneMarie Swaim; Laura E Thompson; Abhai Tripathi; Craig A Fletcher; Erin M Shirk; Henry Sun; M Anna Kowalska; Karen Fox-Talbot; David Sullivan; Fidel Zavala; Craig N Morrell
Journal:  Cell Host Microbe       Date:  2008-08-14       Impact factor: 21.023

7.  The influence of platelet activating factor on the effects of platelet agonists and antiplatelet agents in vitro.

Authors:  Friederike K Keating; David J Schneider
Journal:  J Thromb Thrombolysis       Date:  2008-06-25       Impact factor: 2.300

8.  Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention.

Authors:  Atul Aggarwal; Burton E Sobel; David J Schneider
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

9.  Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4).

Authors:  Anne Bertling; Martin F Brodde; Mayken Visser; Janina Treffon; Michelle Fennen; Anke C Fender; Reinhard Kelsch; Beate E Kehrel
Journal:  Transfus Med Hemother       Date:  2017-08-11       Impact factor: 3.747

10.  Dual regulation of glycogen synthase kinase 3 (GSK3)α/β by protein kinase C (PKC)α and Akt promotes thrombin-mediated integrin αIIbβ3 activation and granule secretion in platelets.

Authors:  Samantha F Moore; Marion T J van den Bosch; Roger W Hunter; Kei Sakamoto; Alastair W Poole; Ingeborg Hers
Journal:  J Biol Chem       Date:  2012-12-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.